Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...
Schrödinger, Inc. remains a complex story with a unique dual business model in drug discovery software, collaborations, and internal drug development. Recent analyst sentiment is mixed, with several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback